Table 4.
Prediction of stability at 6 months from administration of anti-fibrotic drugs in multivariate analysis
| variable | model 1 | model 2 | model 3 (model 1 + model 2) | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Change in SP-A in 3 months (%) | 0.88 (0.80–0.97) | < 0.01 | – | – | 0.89 (0.76–0.98) | < 0.05 |
| Change in SP-D in 3 months (%) | 1.10 (0.98–1.05) | 0.28 | – | – | 1.04 (0.99–1.13) | 0.09 |
| Change in KL-6 in 3 months (%) | 0.99 (0.95–1.03) | 0.67 | – | – | 0.99 (0.92–1.04) | 0.71 |
| Change in SP-A in 6 months (%) | – | – | 0.90 (0.84–0.97) | < 0.01 | 0.88 (0.76–0.96) | < 0.01 |
| Change in SP-D in 6 months (%) | – | – | 0.98 (0.92–1.03) | 0.37 | 0.98 (0.90–1.04) | 0.49 |
| Change in KL-6 in 6 months (%) | – | – | 0.95 (0.90–1.01) | 0.05 | 0.96 (0.87–1.03) | 0.30 |
OR odd’s ratio; SP surfactant protein; KL-6 Krebs von den Lungen-6